IAGIM Drug Development Association signed close to a dozen
generic drug development projects in the 1Q of this year with
generic houses as diverse as Argentina, Brazil, China, Ireland,
Malaysia, Singapore, US, UK, and New Zealand. Leading Generic
Drug Manufacturers purchased IT data, including CMC and Analytical
and Bioavailability data profiles from IAGIM Association.
Isofarma (Brazil) has extended its well known sterile products
and entered the Brazilian generic tablet and capsule market
by purchasing IAGIM full CMC data packages. The Norton (UK),
Ivax (Ireland) and Zenith Goldline (US) top selling generic
lines derived several of their key product know-how from the
IAGIM Research and Development laboratories and scale-up manufacturing
units utilizing IAGIM extended benefit plans for generic and
innovative developers.
Product development data supplied up to validated full scale
commercial batches in all the proposed marketing strengths slashed
the companies generic pipeline queue from 9 -15 months of time
saved in formulating from scratch.. Within 89 days from IT transfer
IAGIM's Tamoxifen 10,20, 30 & 40 mg passes US / EU bioequivalent
study.
IAGIM has spread it's state-of-the-art drug development know-how
and manufacturing technology in approximately 70 countries with
regular drug development/formulation seminars and workshops
conducted on all five continents. India has become a major purchaser
of IAGIM information technology (IT) counting major Indian drug
houses as Cipla, Novartis, Nicholas Piramal, Randbaxy, Sun,
Wochardt and Dr. Reddys.
For additional information contact
IAGIM http://www.iagim.org or fax. US + (1)-561-865-6147
Pharma Today
|